Dutch Statistics on Lung Cancer: Sobering Experience for a New Approach  by Zwitter, Matjaz
EDITORIAL
Dutch Statistics on Lung Cancer
Sobering Experience for a New Approach
Matjaz Zwitter, MD, PhD
In this issue of the journal, van der Drift et al.1 present data from the Netherlands CancerRegistry on non-small cell lung cancer (NSCLC) over a 20-year period. The survey
includes a remarkable total number of 147,760 patients with microscopically confirmed
NSCLC. In the period between 1989 and 2009, the proportion of women more than
doubled (from 15 to 34%); squamous cell carcinoma decreased (from 52 to 29%); the
proportion of patients with stage IV NSCLC increased (from 24 to 44%); and the
proportion of patients who received treatment according to the current guidelines for each
particular stage increased. Still, even in the most recent cohort of patients treated between
2005 and 2009, only 27% of all patients with stage II received (neo)adjuvant chemother-
apy; not more than 45% of those with stage IIIA were treated by chemoradiotherapy; and
only 49% of patients with stage IV NSCLC received any form of systemic therapy. The
proportion of patients with stage II treated with surgery actually decreased: from 64% in
1989–1994 to 57% in 2005–2009. Although survival for each particular stage improved,
the survey revealed only a marginal improvement of 5-year survival for all patients: 14.8%
for the cohort treated in 1989–1994 compared with 16.1% for those treated between 2004
and 2009.
There is no doubt that longitudinal surveys contribute important information
regarding the trends in the burden of a specific disease. However, interpretation of the
findings requires much more than simple statistics. Rather, we are dealing with a delicate
interplay of a changing biology of the disease, trends in microscopic verification,
differences in diagnostics leading to stage migration, and new approaches in treatment.
My aim is to comment on the Dutch survey through the perspective of these four elements:
biology, verification, stage migration, and treatment. I will then conclude with proposals
for a more reasonable application of the existing knowledge, for guidelines which should
be closer to the clinical situation, and for future clinical research.
Regarding the biology of the disease, there was a substantial increase in the
proportion of adenocarcinoma and decrease of squamous cell cancer and small cell cancer
over the past three decades.2 It has been supposed that these changes are related to the
declining tobacco consumption in many developed countries, to the now prevailing use of
light cigarettes which allow deeper inhalation, and to an increase of the incidence of lung
cancer among nonsmokers. A reversed ratio of the squamous carcinoma versus adeno-
carcinoma was also recorded in the Dutch statistics. In comparison with squamous
carcinoma, adenocarcinoma more often starts at the periphery with few early symptoms,
runs a more prolonged course, and is sensitive to a wider spectrum of drugs used in the
treatment of lung cancer. However, late relapses in adenocarcinoma are more common
than in squamous carcinoma. Hence, I believe that a higher proportion of nonsquamous
carcinoma in recent cohorts of the Dutch survey probably did not influence long-term
survival.
The second limitation in the interpretation of longitudinal surveys is linked to
differences in diagnostics over longer time periods. Surveys such as the Dutch one on
non-small cell lung cancer do not include patients without histologic or cytologic
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diagnosis for whom the type of cancer is unknown. From the
clinical standpoint, the decision to proceed with diagnostics
for verification of a suspected lung tumor depends on tech-
nical possibilities and on the therapeutic implications of the
diagnostics. New diagnostic procedures in recent years offer
noninvasive or minimally invasive possibilities to obtain
microscopic diagnosis. In addition, clinicians are now more
likely to proceed with verification also for frail and/or elderly
patients for whom systemic therapy would not have been
considered a few decades ago; this is particularly true after
the introduction of tyrosine kinase inhibitors. Although van
der Drift et al. did not mention the proportion of patients with
microscopically unconfirmed lung cancer, data from the Can-
cer Registry of Slovenia reveal that the percentage of patients
with microscopically unconfirmed lung cancer decreased
from 10.0% in 1989 to 7.7% in 2008.3 The Dutch survey—
like any other analysis of the data from a cancer registry—did
not include a crucial prognostic parameter: performance sta-
tus. However, following what was said regarding the trends in
verification, it is very likely that recent cohorts of patients
included a greater proportion of frail patients, leading to
worse overall survival.
Stage migration due to more precise diagnostics is a
well-known phenomenon, mentioned also in the discussion of
the article by van der Drift et al. Stage migration contributed
to a higher proportion of patients with advanced disease and
also to better survival of patients with each particular stage in
recent cohorts. However, stage migration (if not followed by
a different therapy) could not influence overall survival.
Finally, the outcome clearly depends also on treatment.
During the last two decades, a broad spectrum of new
possibilities for surgery, radiotherapy, and systemic treatment
for lung cancer have been tested in clinical trials. New
concepts have emerged: neoadjuvant and adjuvant chemo-
therapy for operable cancer; combined chemoradiotherapy
for locally advanced cancer; and maintenance treatment and
second-line treatment for advanced lung cancer. Supported
by randomized clinical trials, these concepts are now pre-
sented as evidence-based medicine and incorporated into the
guidelines.
Surveys such as the one from the Netherlands Cancer
Registry unfortunately do not contain precise information on
the indication (palliative versus curative), timing, and type of
particular treatment(s). Nevertheless, two comments will be
made. The first one concerns a decrease in surgical treatment
for NSCLC in stage II. Despite more precise diagnostics, new
surgical techniques, better perioperative care, and (neo)adju-
vant chemotherapy in recent years, fewer patients with stage
II were treated with surgery. An explanation should be sought
in the attitude of thoracic surgeons and thoracic multidici-
plinary teams in the Netherlands; their reluctance to indicate
surgery for such cases should be reconsidered.
The second comment is of a more fundamental char-
acter and is best formulated by a question: how can it be that
even in the most recent cohorts, more than half of patients
with NSCLC did not receive treatment according to the
widely accepted guidelines? As all cancer care is free for
every citizen in the Netherlands, the decision is obviously not
due to economic considerations; equally unlikely is lack of
knowledge in one of the medically most developed countries.
If the availability of the treatment or physician’s knowledge
is not to blame, then the answer lies in the guidelines
themselves. At least for the case of lung cancer (not to
mention other malignancies), the knowledge formulated in
evidence-based medicine is based on selected series of pa-
tients and is not applicable to an average patient in clinical
practice. This thesis is supported by a recent report that only
35% of patients with advanced NSCLC would meet the
eligibility criteria for at least one of the three active clinical
trials.4 For some categories of patients, the gap between an
ideal patient from the guidelines and the average patient from
clinical practice is especially wide. As an example, concur-
rent chemoradiotherapy is the proposed optimal treatment for
NSCLC in stage III; yet, my estimate is that more than 80%
of these patients present with bulky tumors and/or significant
comorbidity and are best treated either by radiotherapy alone
or with induction chemotherapy followed by radiotherapy.
Stage III NSCLC is not a rare phenomenon: in many reports
including the Dutch series, 30 to 35% of patients have stage
III disease. Still, many trials on concurrent chemoradiother-
apy had to close due to slow recruitment. Yes, concurrent
chemoradiotherapy is the optimal treatment for a minority of
the best stage III patients. For the rest, we have no firm
evidence-based recommendation.
The very modest improvement in 5-year survival in
Netherlands over the past 20 years—from 14.8 to 16.1%—is
a sobering, if not a disappointing, experience. As I said, the
changing biology of lung cancer with a shift from squamous
carcinoma to adenocarcinoma probably did not influence the
outcome, and the supposed increased proportion of frail
patients in recent years in whom the diagnosis was micro-
scopically confirmed could not change much. The two real
obstacles to a substantial progress against lung cancer are the
pessimism which still prevails in our daily decisions and the
direction of current research which turned away from ques-
tions of crucial relevance for the clinical practice and almost
entirely sank into commercially motivated projects.
How to combat pessimism? The motto should be every
patient counts. Guidelines should help in decisions but should
not limit our mission to follow the best chances for a partic-
ular patient, rather than the statistics of a surgical or any other
department. I already said that it is difficult to understand the
reluctance of the Dutch (and probably also other) surgeons to
treat patients with stage II disease. The same positive ap-
proach should apply to stage IIIA, especially if in remission
after induction chemotherapy. Furthermore, selected patients
in good performance status with oligometastatic stage IV may
benefit from aggressive combined-modality treatment.5 Even
the “Berlin Wall” of stage IV may not be as invincible as
considered until recently: our series of intermittent chemo-
therapy and tyrosine kinase inhibitor for metastatic adenocar-
cinoma with activating mutations of epidermal growth factor
receptor led to complete and durable remissions in a substan-
tial proportion of patients.6
The last and definitively the most important point
should be our constant dedication to clinically relevant re-
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search. Non-small cell lung cancer is now among the leading
fields of clinical cancer research; yet, the Dutch survey shows
that this tree grows in a shadow and has so far yielded little
fruit. Although commercial sponsors have indeed brought
substantial resources into research, the dominance of money
over clinical importance has its dark sides. The research
question and the design of trials follow the interests of a
sponsor, rather than the hierarchy of a clinical problem. It is
clear that commercial sponsors have little interest in support-
ing trials of radiotherapy, surgery, or drugs for which the
patent has expired or will expire before projected trial pub-
lication. A brief survey through clinical trials on NSCLC
published in 2010, and included in the PubMed database,
reveals that 174 trials or 66.7% of all published trials were
devoted to treatment of metastatic lung cancer; only 9 trials
(3.4% of all published trials) were large randomized phase III
trials on stage I–III disease. Yet, defining optimal surgery,
radiotherapy, and combined-modality treatment for nonmeta-
static disease is of outmost importance for saving as many
lives as possible.
Seven years ago, Macbeth et al.7 published an initiative
for a world strategy for clinical trials: “Present and future
lung cancer patients and their health professionals throughout
the world need relevant questions about treatment answered
as efficiently and reliably as possible. To do this we believe
we all need to collaborate and run much larger trials over
much shorter time periods on topics that are widely applica-
ble. ” To our knowledge, this initiative unfortunately did not
lead to action.
As emphasized by Peto and Baigent,8 we need simple,
large-scale trials designed and controlled by academic cen-
ters. We need relevant and simple questions, simple trial
design, and broad inclusion criteria. Frail and elderly patients
and those with comorbidity who cannot tolerate the standard
treatment should not be excluded from a trial, rather they
should be offered a modified less intensive schedule. On this
basis, we will be able to formulate guidelines applicable in
clinical practice, and we may hope for a better future for our
patients.
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